-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JTjIaLjV3yl+PRgfiOAgIojio3Y9mRBQ5Rjb9hcT+HbI0E3ZuhYaY4ohQVHDc/f3 30HNJwaOg/Z94Vhc67iMaA== 0001279569-09-000421.txt : 20090330 0001279569-09-000421.hdr.sgml : 20090330 20090330132836 ACCESSION NUMBER: 0001279569-09-000421 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090330 FILED AS OF DATE: 20090330 DATE AS OF CHANGE: 20090330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOVASC INC CENTRAL INDEX KEY: 0001399708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53363 FILM NUMBER: 09713256 BUSINESS ADDRESS: STREET 1: 2135 13700 Mayfield place STREET 2: richmond british columbia CITY: Canada STATE: A1 ZIP: 00000 BUSINESS PHONE: 604-270-4344 MAIL ADDRESS: STREET 1: 2135 13700 Mayfield place STREET 2: richmond british columbia CITY: Canada STATE: A1 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Medical Ventures Corp DATE OF NAME CHANGE: 20070516 6-K 1 neovasc6k.htm FORM 6-K neovasc6k.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March, 2009
 
Commission File Number: 000-53363
 
NEOVASC INC.
(Exact name of Registrant as specified in its charter)
 
Suite 2135 - 13700 Mayfield Place
Richmond, British Columbia, Canada, V6V 2E4
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
x Form 20-F   o Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes o   No x
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _________
 
 
 
 
 
 
SUBMITTED HEREWITH
 
Exhibits
   Description
     
99.1
   News Release Dated March 30, 2009 - Neovasc to Raise $2 Million in Non-Brokered Private Placement
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  NEOVASC INC.
  (Registrant)
     
Date: March 30, 2009 By: /s/ Alexei Marko
   
    Alexei Marko
  Title: Chief Executive Officer
 
EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 30, 2009 ex991.htm 
 
Exhibit 99.1
News release via Canada NewsWire, Vancouver 604-669-7764

	    Attention Business Editors:
	    Neovasc to Raise $2 Million in Non-Brokered Private Placement

	    <<
	    --Proceeds Will Advance Key New Products Including Completing CE Mark
	    Application for the Reducer(TM) Stent--
	    >>

	    VANCOUVER, March 30 /CNW/ - Neovasc Inc. (TSXV: NVC) today announced that
it intends to undertake a non-brokered private placement of approximately 9.52
million units at the price of $0.21 per unit for aggregate gross proceeds of
$2.0 million. The proceeds of the offering will be used for continued
development of a suite of new products and to help fund continuing operations.
The completion of the private placement is subject to TSX Venture Exchange
approval and the execution of definitive documentation with investors. The
securities issued pursuant to the offering will be subject to a four-month
hold period from the date of issuance. The private placement is led by members
of the Frost Group, LLC.
	    Each unit consists of one common share of Neovasc stock and one-half of
one common share purchase warrant of Neovasc stock. Each whole warrant will
entitle the holder thereof to purchase one common share of Neovasc stock at
the exercise price of $0.30 per share for a period of one year after the
closing date of the offering. All of the proceeds will be placed with company
insiders.
	    "This financing provides us with additional operating flexibility to
advance the products that we expect to be key growth drivers for Neovasc,
especially our innovative Reducer(TM) stent for the treatment of refractory
angina," said Alexei Marko, chief executive officer of Neovasc. "We are
pleased at the confidence in Neovasc evidenced by the participation of
insiders in this financing, which strengthens our ability to execute on the
focused strategy we implemented late last year."

	    About Neovasc Inc.

	    Neovasc Inc. is a new specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing vascular and
surgical marketplace. The company's current products include, Metricath(R) for
intravascular measurement and Peripatch(TM) surgical tissue and staple line
reinforcement products. Neovasc has a development pipeline of innovative new
products, and provides contract medical device development and manufacturing
services. For more information, visit: www.neovasc.com.

	    About Frost Group, LLC

	    The Frost Group, LLC, is a private investment firm based in Miami. The
Frost Group is led by Dr. Phillip Frost, and includes Jane Hsiao, Ph.D., Rao
Uppaluri, Ph.D., and Steven D. Rubin, a team that has been together in various
capacities for over 22 years. Since its formation in October 2006, the Frost
Group has invested over $140 million in various companies and technologies in
the United States and abroad. These investments include stakes in the areas of
pharmaceuticals, diagnostic devices, medical devices, developmental education
and entertainment for children, telecommunications, sports licensing, aviation
services, software for seismic data analysis, and new materials for computer
chips.

	    Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.

	    %CIK: 0001399708

	    /For further information: Corporate contact: Neovasc Inc., Chris Clark,
(604) 248-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners,
Barbara Lindheim, (212) 918-4650/
	    (NVC.)

CO:  Neovasc Inc.

CNW 07:32e 30-MAR-09
-----END PRIVACY-ENHANCED MESSAGE-----